What is the recommended management of human metapneumovirus (HMPV) infection, including diagnosis, supportive care, and treatment options, in children, older adults, and immunocompromised patients?

Management of Human Metapneumovirus (HMPV) Infection

HMPV infection requires supportive care only, as no specific antiviral therapy or vaccine is currently approved for clinical use. 1, 2

Diagnosis

Molecular testing (nucleic acid amplification test/RT-PCR) is the diagnostic method of choice for HMPV, as viral culture is difficult and time-consuming. 1, 3

• Direct antigen detection (DAD) and viral isolation in culture (VIC) are available but increasingly replaced by multiplex nucleic acid testing that can identify HMPV along with other respiratory viruses. 1
• Testing should be performed in symptomatic patients, particularly those requiring hospitalization, to guide infection control measures and avoid unnecessary antibiotic use. 1
• Asymptomatic shedding occurs in up to 41% of immunocompromised patients, complicating interpretation of positive results. 1

Risk Stratification

High-risk populations requiring closer monitoring include:

• Infants 0-5 months old 4
• Adults >65 years old 4
• Immunocompromised patients (hematopoietic stem cell transplant recipients, leukemia patients) 1, 4
• Patients with chronic lung disease (COPD, asthma) 5
• Presence of high viral load or coinfection with other respiratory viruses (especially RSV) 4

Treatment Approach

Supportive Care (All Patients)

All HMPV infections should be managed with supportive measures as primary therapy:

• Oxygen supplementation to maintain SpO₂ >90% 1
• Hydration and nutritional support 1
• Antipyretics for fever management 1
• Respiratory support escalation as needed (supplemental oxygen → noninvasive ventilation → mechanical ventilation) 1

Antiviral Considerations (Severe Cases Only)

No antiviral therapy has proven efficacy for HMPV. 1 However, some centers consider empiric treatment in severely ill immunocompromised patients despite lack of supporting evidence:

• Ribavirin (with or without IVIG) may be considered in HMPV lower respiratory tract disease in immunocompromised patients, though efficacy is unclear. 1, 4
• This approach is extrapolated from RSV management protocols but lacks specific evidence for HMPV. 1
• Monoclonal antibodies targeting the fusion protein show promise in preclinical studies but none are approved for clinical use. 2, 6

Bacterial Superinfection Management

If bacterial superinfection is suspected (new fever, increased respiratory distress, radiographic progression after initial improvement), empiric antibiotics should target:

• Streptococcus pneumoniae (most common) 1
• Staphylococcus aureus 1
• Haemophilus influenzae 1

Recommended empiric regimens for suspected bacterial superinfection:

• Amoxicillin-clavulanate, cefpodoxime, cefprozil, cefuroxime, or respiratory fluoroquinolone 1

Population-Specific Management

Children

• Outpatient management is appropriate for mild cases with adequate oral intake and oxygen saturation >90% in room air. 1

• Hospitalization criteria include: 1

  • SpO₂ <90% in room air
  • Respiratory distress (increased work of breathing, tachypnea)
  • Inability to maintain hydration
  • Age <3 months with fever
  • Underlying cardiopulmonary disease

• ICU admission if: 1

  • Requiring mechanical ventilation
  • SpO₂ <92% on FiO₂ ≥0.50
  • Impending respiratory failure
  • Altered mental status from hypoxemia/hypercarbia

Older Adults

• Lower threshold for hospitalization given higher risk of severe disease 4, 3
• Monitor closely for exacerbation of underlying chronic conditions (COPD, heart failure) 5
• Consider bacterial superinfection if clinical deterioration occurs 1

Immunocompromised Patients

HMPV causes upper respiratory tract infection progressing to lower respiratory tract disease in 13-37% of hematopoietic stem cell transplant recipients, with mortality of 10-30%. 1

• Risk factors for progression to lower respiratory tract disease: 1

  • Corticosteroid exposure
  • Neutropenia and lymphopenia
  • Infection within first 3 months post-transplant
  • Coinfections with other pathogens

• Management approach: 1

  • Aggressive supportive care
  • Consider ribavirin ± IVIG for lower respiratory tract disease (despite lack of proven efficacy)
  • Reduce immunosuppression if feasible
  • Monitor for bacterial, fungal, and viral coinfections

Infection Control

Implement contact and droplet precautions for hospitalized patients given high rates of nosocomial transmission and asymptomatic shedding. 1

• Estimated incubation period: 3.2 days (95% CI 2.8-3.7) 1
• Viral shedding can be prolonged in immunocompromised patients 1

Discharge Criteria

Patients may be discharged when: 1

• Clinical improvement with decreased fever for 12-24 hours
• SpO₂ >90% in room air for 12-24 hours
• Adequate oral intake
• Stable or baseline mental status
• No increased work of breathing or sustained tachypnea

Key Clinical Pitfalls

• Do not delay supportive care while awaiting viral testing results. 1
• Avoid unnecessary antibiotics in confirmed viral infection without evidence of bacterial superinfection. 1
• Do not assume mild disease in high-risk populations—early hospitalization may prevent deterioration. 4
• Coinfections are common (bacteria, fungi, CMV, other respiratory viruses) in immunocompromised patients and obscure attributable morbidity. 1